Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
5IMSC - Implant Sciences in ETD deal with Brazilian logistics co.:
http://finance.yahoo.com/news/global-brazilian-logistics-company-selects-110000376.html
5IMSC - Implant Sciences in ETD deal with Brazilian logistics co.:
http://finance.yahoo.com/news/global-brazilian-logistics-company-selects-110000376.html
$IMSC - Implant Sciences Sells TSA-Approved Explosives Trace Detectors to R&M Trucking
WILMINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its TSA-approved QS-B220 desktop explosives trace detector to Illinois-based R&M Trucking. The systems were purchased to replace TSA grandfathered systems, which are currently approved to screen cargo, but have a stated expiration date of January 1, 2014. R&M is a full service trucking company that is also a Certified Cargo Screening Facility (CCSF). Transportation and logistics companies with CCSF status are certified by the TSA to screen air cargo packages for explosives before they are loaded onto airplanes, and are required to use TSA-approved screening systems.
"R&M Trucking appreciated the QS-B220's easy-to-use and easy-to-maintain design which delivers a low total cost of ownership over the lifecycle of the system," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "A growing number of CCSFs are choosing our QS-B220 for expanding capacity with new ETD systems, as well as for replacing systems that are scheduled to lose their grandfathered TSA-approval status. In January 2014, several older systems from competing manufacturers currently allowed under a grandfathered status will no longer be in compliance with TSA requirements. The QS-B220 offers freight forwarders, airlines, trucking and logistics companies an innovative alternative that is truly the new standard in explosives trace detection."
About R&M Trucking
R&M Trucking is a full service trucking company that maintains high standards for service and customer satisfaction. R&M's fleet of 166 company owned trucks can provide a specialized transportation and logistical network at a competitive price. The company employs 236 drivers who are equipped with the latest communications technology enabling R&M to provide immediate responses to customer's needs. All drivers are certified to handle hazardous material and are educated in the rules of TSA, C-TPAT and OSHA regulations.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
http://finance.yahoo.com/news/implant-sciences-sells-tsa-approved-110000230.html
$IMSC - Implant Sciences Sells TSA-Approved Explosives Trace Detectors to R&M Trucking
WILMINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its TSA-approved QS-B220 desktop explosives trace detector to Illinois-based R&M Trucking. The systems were purchased to replace TSA grandfathered systems, which are currently approved to screen cargo, but have a stated expiration date of January 1, 2014. R&M is a full service trucking company that is also a Certified Cargo Screening Facility (CCSF). Transportation and logistics companies with CCSF status are certified by the TSA to screen air cargo packages for explosives before they are loaded onto airplanes, and are required to use TSA-approved screening systems.
"R&M Trucking appreciated the QS-B220's easy-to-use and easy-to-maintain design which delivers a low total cost of ownership over the lifecycle of the system," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "A growing number of CCSFs are choosing our QS-B220 for expanding capacity with new ETD systems, as well as for replacing systems that are scheduled to lose their grandfathered TSA-approval status. In January 2014, several older systems from competing manufacturers currently allowed under a grandfathered status will no longer be in compliance with TSA requirements. The QS-B220 offers freight forwarders, airlines, trucking and logistics companies an innovative alternative that is truly the new standard in explosives trace detection."
About R&M Trucking
R&M Trucking is a full service trucking company that maintains high standards for service and customer satisfaction. R&M's fleet of 166 company owned trucks can provide a specialized transportation and logistical network at a competitive price. The company employs 236 drivers who are equipped with the latest communications technology enabling R&M to provide immediate responses to customer's needs. All drivers are certified to handle hazardous material and are educated in the rules of TSA, C-TPAT and OSHA regulations.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
http://finance.yahoo.com/news/implant-sciences-sells-tsa-approved-110000230.html
$IMSC - Implant Sciences Sells TSA-Approved Explosives Trace Detectors to R&M Trucking
WILMINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its TSA-approved QS-B220 desktop explosives trace detector to Illinois-based R&M Trucking. The systems were purchased to replace TSA grandfathered systems, which are currently approved to screen cargo, but have a stated expiration date of January 1, 2014. R&M is a full service trucking company that is also a Certified Cargo Screening Facility (CCSF). Transportation and logistics companies with CCSF status are certified by the TSA to screen air cargo packages for explosives before they are loaded onto airplanes, and are required to use TSA-approved screening systems.
"R&M Trucking appreciated the QS-B220's easy-to-use and easy-to-maintain design which delivers a low total cost of ownership over the lifecycle of the system," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "A growing number of CCSFs are choosing our QS-B220 for expanding capacity with new ETD systems, as well as for replacing systems that are scheduled to lose their grandfathered TSA-approval status. In January 2014, several older systems from competing manufacturers currently allowed under a grandfathered status will no longer be in compliance with TSA requirements. The QS-B220 offers freight forwarders, airlines, trucking and logistics companies an innovative alternative that is truly the new standard in explosives trace detection."
About R&M Trucking
R&M Trucking is a full service trucking company that maintains high standards for service and customer satisfaction. R&M's fleet of 166 company owned trucks can provide a specialized transportation and logistical network at a competitive price. The company employs 236 drivers who are equipped with the latest communications technology enabling R&M to provide immediate responses to customer's needs. All drivers are certified to handle hazardous material and are educated in the rules of TSA, C-TPAT and OSHA regulations.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
http://finance.yahoo.com/news/implant-sciences-sells-tsa-approved-110000230.html
U.S. Government agencies buy Implant Sciences’ QS-B220 explosives trace detector
Government Security News - 2013-09-23
Implant Sciences Corp., a supplier of systems and sensors for homeland security and defense markets, announced On September 23 that, in recent weeks, U.S. Government agencies purchased multiple QS-B220 desktop explosives trace detectors.
These purchases were made possible due to Implant Sciences' QS-B220 successfully completing Independent Testing & Evaluation (IT&E) with the Transportation Security Laboratory (TSL).
"The QS-B220's strong performance in TSL testing has opened the door to new opportunities within the U.S. Government, and in an environment of growing budgetary pressure, the cost advantages of the product really stand out,” said Darryl Jones, Implant Sciences' vice president of sales and marketing. “Implant Sciences' products offer superior performance couple with a compelling value proposition for both government and commercial clients."
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products, says an Implant Sciences news release.
$IMSC - Implant Sciences hires industry sales veteran from Morpho, Smiths and Rapiscan:
Implant Sciences Continues to Attract Top Talent as It Adds Industry Veteran to Sales Team
WILMINGTON, MA--(Marketwired - Sep 23, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the appointment of Hector Giraldo as Sales Director for Latin America. Mr. Giraldo has over 15 years of experience in growing sales in Latin America with security industry companies including Morpho, Smiths Detection, and Rapiscan.
Mr. Giraldo, who is fluent in both Spanish and Portuguese, was most recently Vice President, International Business Development at The Provectus Group, a provider of integrated security solutions for international public safety. Prior, he was Director of Sales and Business Development at Morpho, formerly L-1, where he concentrated on the development of sales and projects with international governments. As Director for Latin America at Rapiscan Systems, Mr. Giraldo oversaw the complete distribution of more than 30 products in 21 countries. He directly managed hiring and training of internal team members, and external channel partners. Prior to joining Rapiscan, Mr. Giraldo was International Sales Manager at Smiths Detection where he was responsible for complete market development in Latin America and the Caribbean, doubling sales in the first year, with over 30% increases in sales in subsequent years. Early in his career, while serving as Technical Sales Representative at Scintrex Analytical & Security, Mr. Giraldo launched a new product family and grew revenues fourfold in the region. He is also a speaker and seminar leader on counter-terrorism technologies and explosives and chemical weapons detection.
"Hector has gained his in-depth industry experience with some of the largest companies in the security equipment business. He's proven his ability to build sales and distribution networks in Latin America that have directly resulted in significant revenue increases," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "We're proud of Implant Sciences' reputation in the industry, not only for our high-performance next-generation explosives and drugs trace detection equipment, but also for being a company where the best and brightest in our industry are choosing to work. We welcome Hector to our team and look forward to increasing our sales in Latin America."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
http://finance.yahoo.com/news/implant-sciences-continues-attract-top-110000062.html
$IMSC - Implant Sciences hires industry sales veteran from Morpho, Smiths and Rapiscan:
Implant Sciences Continues to Attract Top Talent as It Adds Industry Veteran to Sales Team
WILMINGTON, MA--(Marketwired - Sep 23, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the appointment of Hector Giraldo as Sales Director for Latin America. Mr. Giraldo has over 15 years of experience in growing sales in Latin America with security industry companies including Morpho, Smiths Detection, and Rapiscan.
Mr. Giraldo, who is fluent in both Spanish and Portuguese, was most recently Vice President, International Business Development at The Provectus Group, a provider of integrated security solutions for international public safety. Prior, he was Director of Sales and Business Development at Morpho, formerly L-1, where he concentrated on the development of sales and projects with international governments. As Director for Latin America at Rapiscan Systems, Mr. Giraldo oversaw the complete distribution of more than 30 products in 21 countries. He directly managed hiring and training of internal team members, and external channel partners. Prior to joining Rapiscan, Mr. Giraldo was International Sales Manager at Smiths Detection where he was responsible for complete market development in Latin America and the Caribbean, doubling sales in the first year, with over 30% increases in sales in subsequent years. Early in his career, while serving as Technical Sales Representative at Scintrex Analytical & Security, Mr. Giraldo launched a new product family and grew revenues fourfold in the region. He is also a speaker and seminar leader on counter-terrorism technologies and explosives and chemical weapons detection.
"Hector has gained his in-depth industry experience with some of the largest companies in the security equipment business. He's proven his ability to build sales and distribution networks in Latin America that have directly resulted in significant revenue increases," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "We're proud of Implant Sciences' reputation in the industry, not only for our high-performance next-generation explosives and drugs trace detection equipment, but also for being a company where the best and brightest in our industry are choosing to work. We welcome Hector to our team and look forward to increasing our sales in Latin America."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
http://finance.yahoo.com/news/implant-sciences-continues-attract-top-110000062.html
$IMSC - Implant Sciences hires industry sales veteran from Morpho, Smiths and Rapiscan:
Implant Sciences Continues to Attract Top Talent as It Adds Industry Veteran to Sales Team
WILMINGTON, MA--(Marketwired - Sep 23, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the appointment of Hector Giraldo as Sales Director for Latin America. Mr. Giraldo has over 15 years of experience in growing sales in Latin America with security industry companies including Morpho, Smiths Detection, and Rapiscan.
Mr. Giraldo, who is fluent in both Spanish and Portuguese, was most recently Vice President, International Business Development at The Provectus Group, a provider of integrated security solutions for international public safety. Prior, he was Director of Sales and Business Development at Morpho, formerly L-1, where he concentrated on the development of sales and projects with international governments. As Director for Latin America at Rapiscan Systems, Mr. Giraldo oversaw the complete distribution of more than 30 products in 21 countries. He directly managed hiring and training of internal team members, and external channel partners. Prior to joining Rapiscan, Mr. Giraldo was International Sales Manager at Smiths Detection where he was responsible for complete market development in Latin America and the Caribbean, doubling sales in the first year, with over 30% increases in sales in subsequent years. Early in his career, while serving as Technical Sales Representative at Scintrex Analytical & Security, Mr. Giraldo launched a new product family and grew revenues fourfold in the region. He is also a speaker and seminar leader on counter-terrorism technologies and explosives and chemical weapons detection.
"Hector has gained his in-depth industry experience with some of the largest companies in the security equipment business. He's proven his ability to build sales and distribution networks in Latin America that have directly resulted in significant revenue increases," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "We're proud of Implant Sciences' reputation in the industry, not only for our high-performance next-generation explosives and drugs trace detection equipment, but also for being a company where the best and brightest in our industry are choosing to work. We welcome Hector to our team and look forward to increasing our sales in Latin America."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
http://finance.yahoo.com/news/implant-sciences-continues-attract-top-110000062.html
al Qaeda behind bloody massacre in Nairobi upscale shopping mall:
http://news.msn.com/world/39-dead-in-kenya-mall-attack-hostages-still-held
$IMSC - Price Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.16 by a fraction of a penny.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Price Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.16 by a fraction of a penny.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Price Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.16 by a fraction of a penny.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Implant Sciences video PR of recent US government orders:
$IMSC - Implant Sciences video PR of recent US government orders:
$IMSC - Implant Sciences video PR of recent US government orders:
$CONX - Corgenix Medical to Host Conference Call to Discuss Fiscal 2013 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company’s financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the annual results to join the call by dialing:
US attendees: (866) 952-1906
International attendees: +1 785 424 1825
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 283-4593 for U.S. participants and +1 402 220 0872 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Contact:
Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations Supervisor
dan@armadamedical.com
$CONX - Corgenix Medical to Host Conference Call to Discuss Fiscal 2013 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company’s financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the annual results to join the call by dialing:
US attendees: (866) 952-1906
International attendees: +1 785 424 1825
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 283-4593 for U.S. participants and +1 402 220 0872 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Contact:
Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations Supervisor
dan@armadamedical.com
$CONX - Corgenix Medical to Host Conference Call to Discuss Fiscal 2013 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company’s financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the annual results to join the call by dialing:
US attendees: (866) 952-1906
International attendees: +1 785 424 1825
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 283-4593 for U.S. participants and +1 402 220 0872 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Contact:
Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations Supervisor
dan@armadamedical.com
Alert Triggered for Implant Sciences Corp
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.15 with a trade of $1.16 at 10:38 AM EDT. It is currently trading higher on the day, up 0.9% to $1.16, on volume of 164,454, which is especially heavy given that there are still several hours left in the trading day.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Alert Triggered for Implant Sciences Corp
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.15 with a trade of $1.16 at 10:38 AM EDT. It is currently trading higher on the day, up 0.9% to $1.16, on volume of 164,454, which is especially heavy given that there are still several hours left in the trading day.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Alert Triggered for Implant Sciences Corp
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.15 with a trade of $1.16 at 10:38 AM EDT. It is currently trading higher on the day, up 0.9% to $1.16, on volume of 164,454, which is especially heavy given that there are still several hours left in the trading day.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Alert Triggered for Implant Sciences Corp
Implant Sciences Corp (IMSC) Price Crossed Above Its 60 Day Moving Average
IMSC crossed above its 60 day moving average of $1.15 with a trade of $1.16 at 10:38 AM EDT. It is currently trading higher on the day, up 0.9% to $1.16, on volume of 164,454, which is especially heavy given that there are still several hours left in the trading day.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.
$IMSC - Let the orders commence!: Multiple U.S. Government Agencies Place Orders for QS-B220 Explosives Trace Detector
Proven Performance of Implant Sciences' Equipment Leads to New Deployments
WILMINGTON, MA -- (Marketwired) -- 09/18/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that, in recent weeks, U.S. Government agencies purchased multiple QS-B220 desktop explosives trace detectors. These purchases were made possible due to Implant Sciences' QS-B220 successfully completing Independent Testing & Evaluation (IT&E) with the Transportation Security Laboratory (TSL).
"The QS-B220's strong performance in TSL testing has opened the door to new opportunities within the U.S. Government, and in an environment of growing budgetary pressure, the cost advantages of the product really stand out. Implant Sciences' products offer superior performance couple with a compelling value proposition for both government and commercial clients," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.
About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Let the orders commence!: Multiple U.S. Government Agencies Place Orders for QS-B220 Explosives Trace Detector
Proven Performance of Implant Sciences' Equipment Leads to New Deployments
WILMINGTON, MA -- (Marketwired) -- 09/18/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that, in recent weeks, U.S. Government agencies purchased multiple QS-B220 desktop explosives trace detectors. These purchases were made possible due to Implant Sciences' QS-B220 successfully completing Independent Testing & Evaluation (IT&E) with the Transportation Security Laboratory (TSL).
"The QS-B220's strong performance in TSL testing has opened the door to new opportunities within the U.S. Government, and in an environment of growing budgetary pressure, the cost advantages of the product really stand out. Implant Sciences' products offer superior performance couple with a compelling value proposition for both government and commercial clients," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.
About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Let the orders commence!: Multiple U.S. Government Agencies Place Orders for QS-B220 Explosives Trace Detector
Proven Performance of Implant Sciences' Equipment Leads to New Deployments
WILMINGTON, MA -- (Marketwired) -- 09/18/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that, in recent weeks, U.S. Government agencies purchased multiple QS-B220 desktop explosives trace detectors. These purchases were made possible due to Implant Sciences' QS-B220 successfully completing Independent Testing & Evaluation (IT&E) with the Transportation Security Laboratory (TSL).
"The QS-B220's strong performance in TSL testing has opened the door to new opportunities within the U.S. Government, and in an environment of growing budgetary pressure, the cost advantages of the product really stand out. Implant Sciences' products offer superior performance couple with a compelling value proposition for both government and commercial clients," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.
About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Let the orders commence!: Multiple U.S. Government Agencies Place Orders for QS-B220 Explosives Trace Detector
Proven Performance of Implant Sciences' Equipment Leads to New Deployments
WILMINGTON, MA -- (Marketwired) -- 09/18/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that, in recent weeks, U.S. Government agencies purchased multiple QS-B220 desktop explosives trace detectors. These purchases were made possible due to Implant Sciences' QS-B220 successfully completing Independent Testing & Evaluation (IT&E) with the Transportation Security Laboratory (TSL).
"The QS-B220's strong performance in TSL testing has opened the door to new opportunities within the U.S. Government, and in an environment of growing budgetary pressure, the cost advantages of the product really stand out. Implant Sciences' products offer superior performance couple with a compelling value proposition for both government and commercial clients," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.
About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Implant Sciences to Demonstrate TSA-Approved QS-B220 Explosives Trace Detector at Miami International Airport West Cargo Area - Yahoo Finance
WILMINGTON, MA--(Marketwired - Sep 17, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the Company will host explosives trace detection briefings and demonstrations of its TSA-approved QS-B220 desktop explosives trace detector at the Miami International Airport on Thursday, September 19, 2013, in the Miami-International Airport West Cargo Area Conference Room - Cargo Building 702, Suite #205. The event is open to individuals involved in air cargo security. Please contact marcom@implantsciences.com for information on how to attend.
"Explosive Trace Detection (ETD) is arguably the best air cargo security technology available today. Important changes are coming when the TSA's grandfathered list of legacy ETD systems lose their approved status on January 1, 2014. This event will provide important information for air cargo facilities looking to replace expiring systems or expand screening operations," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
http://finance.yahoo.com/news/implant-sciences-demonstrate-tsa-approved-110000122.html
$IMSC - Implant Sciences to Demonstrate TSA-Approved QS-B220 Explosives Trace Detector at Miami International Airport West Cargo Area - Yahoo Finance
WILMINGTON, MA--(Marketwired - Sep 17, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the Company will host explosives trace detection briefings and demonstrations of its TSA-approved QS-B220 desktop explosives trace detector at the Miami International Airport on Thursday, September 19, 2013, in the Miami-International Airport West Cargo Area Conference Room - Cargo Building 702, Suite #205. The event is open to individuals involved in air cargo security. Please contact marcom@implantsciences.com for information on how to attend.
"Explosive Trace Detection (ETD) is arguably the best air cargo security technology available today. Important changes are coming when the TSA's grandfathered list of legacy ETD systems lose their approved status on January 1, 2014. This event will provide important information for air cargo facilities looking to replace expiring systems or expand screening operations," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
http://finance.yahoo.com/news/implant-sciences-demonstrate-tsa-approved-110000122.html
$IMSC - Implant Sciences to Demonstrate TSA-Approved QS-B220 Explosives Trace Detector at Miami International Airport West Cargo Area - Yahoo Finance
WILMINGTON, MA--(Marketwired - Sep 17, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the Company will host explosives trace detection briefings and demonstrations of its TSA-approved QS-B220 desktop explosives trace detector at the Miami International Airport on Thursday, September 19, 2013, in the Miami-International Airport West Cargo Area Conference Room - Cargo Building 702, Suite #205. The event is open to individuals involved in air cargo security. Please contact marcom@implantsciences.com for information on how to attend.
"Explosive Trace Detection (ETD) is arguably the best air cargo security technology available today. Important changes are coming when the TSA's grandfathered list of legacy ETD systems lose their approved status on January 1, 2014. This event will provide important information for air cargo facilities looking to replace expiring systems or expand screening operations," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
http://finance.yahoo.com/news/implant-sciences-demonstrate-tsa-approved-110000122.html
$IMSC - Implant Sciences Receives State Grant for Training Manufacturing Employees at Its New 58,000 Sq. Ft. Facility
ISO 9001 and ISO 14001 Training Program Supports Excellence in Manufacturing for Made-in-the-USA High-Tech Systems
WILMINGTON, MA -- (Marketwired) -- 09/12/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the start of a new ISO 9001 and ISO 14001 training program. This project supports the Company's expanded world class manufacturing operations. The training program is funded by a Workforce Training Fund grant through the Commonwealth of Massachusetts, executive office of Labor and Workforce Development. The grant program is administered by the Commonwealth Corporation.
"One of the major drivers of our recent move into our new 58,000 square foot facility was to have the room to grow our manufacturing capability to meet anticipated demand. This will require training many new employees in the ISO 9001 and ISO 14001 practices demanded in our industry," commented Brenda Baron, Implant Sciences' Vice President of Manufacturing.
"We use contract manufacturing for the QS-H150, but build the QS-B220 product in our facility," added Glenn D. Bolduc, President and CEO of Implant Sciences. "Orders continue to come for our QS-B220 product, and we currently have shipments scheduled into next quarter. We are pleased to receive the state grant, which helps train our employees, while we increase U.S. manufacturing jobs."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Implant Sciences Receives State Grant for Training Manufacturing Employees at Its New 58,000 Sq. Ft. Facility
ISO 9001 and ISO 14001 Training Program Supports Excellence in Manufacturing for Made-in-the-USA High-Tech Systems
WILMINGTON, MA -- (Marketwired) -- 09/12/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the start of a new ISO 9001 and ISO 14001 training program. This project supports the Company's expanded world class manufacturing operations. The training program is funded by a Workforce Training Fund grant through the Commonwealth of Massachusetts, executive office of Labor and Workforce Development. The grant program is administered by the Commonwealth Corporation.
"One of the major drivers of our recent move into our new 58,000 square foot facility was to have the room to grow our manufacturing capability to meet anticipated demand. This will require training many new employees in the ISO 9001 and ISO 14001 practices demanded in our industry," commented Brenda Baron, Implant Sciences' Vice President of Manufacturing.
"We use contract manufacturing for the QS-H150, but build the QS-B220 product in our facility," added Glenn D. Bolduc, President and CEO of Implant Sciences. "Orders continue to come for our QS-B220 product, and we currently have shipments scheduled into next quarter. We are pleased to receive the state grant, which helps train our employees, while we increase U.S. manufacturing jobs."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$IMSC - Implant Sciences Receives State Grant for Training Manufacturing Employees at Its New 58,000 Sq. Ft. Facility
ISO 9001 and ISO 14001 Training Program Supports Excellence in Manufacturing for Made-in-the-USA High-Tech Systems
WILMINGTON, MA -- (Marketwired) -- 09/12/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the start of a new ISO 9001 and ISO 14001 training program. This project supports the Company's expanded world class manufacturing operations. The training program is funded by a Workforce Training Fund grant through the Commonwealth of Massachusetts, executive office of Labor and Workforce Development. The grant program is administered by the Commonwealth Corporation.
"One of the major drivers of our recent move into our new 58,000 square foot facility was to have the room to grow our manufacturing capability to meet anticipated demand. This will require training many new employees in the ISO 9001 and ISO 14001 practices demanded in our industry," commented Brenda Baron, Implant Sciences' Vice President of Manufacturing.
"We use contract manufacturing for the QS-H150, but build the QS-B220 product in our facility," added Glenn D. Bolduc, President and CEO of Implant Sciences. "Orders continue to come for our QS-B220 product, and we currently have shipments scheduled into next quarter. We are pleased to receive the state grant, which helps train our employees, while we increase U.S. manufacturing jobs."
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Source: Implant Sciences Corporation
$CONX - Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
9:15 AM ET 9/10/13 | BusinessWire
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
The New Agreement grants a worldwide license to Corgenix, to utilize the AtherOx(R) technology to exclusively develop and manufacture, and co-exclusively sell diagnostic products during the term of the Agreement, which expires in 2022. In Japan, Corgenix will have the exclusive rights to utilize the AtherOx(R) technology to develop, manufacture and use, but not to sell the related AtherOx(R) products other than at the direction of Dr. Matsuura. Pursuant to the new Agreement, Corgenix will have to achieve certain specified milestones at each of the three anniversaries after the effective date (September 3, 2013).
Previous clinical data presented at several scientific and medical meetings demonstrated a significant correlation between serum levels of the patented AtherOx(R) bio-markers and cardiovascular disease. Luis Lopez, MD, Corgenix' Medical Director, said "Interestingly, data from the studies suggests that AtherOx alone or when combined with anti-phospholipid antibodies predict an increased risk for vascular complications in coronary artery disease patients. In addition, the findings indicate important relationships between AtherOx(R) and the severity of cardiovascular disease."
Commenting on today's announcement, Douglass Simpson, President and CEO of Corgenix, stated, "We are extremely excited to renew and expand our relationship with Dr. Matsuura and retain the rights to the AtherOx(R) technology. We believe this unique science targets a significant worldwide clinical need, and we look forward to seeing additional data over the next few years, leading to the opportunity to bring these products to the market. As new clinical findings continue to validate the utility of AtherOx(R), we anticipate that this technology has the potential to become an important addition to medical care worldwide."
About AtherOx(R)
Corgenix originally licensed the proprietary AtherOx(R) technology in 2002 from Dr. Matsuura. During the ensuing years, Corgenix has incorporated this technology into products, conducting multiple studies that further validate the impressive preclinical data generated by Professor Matsuura. The AtherOx(R) technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI (Ox LDL/B2GPI). Although oxLDL has been implicated in atherosclerotic cardiovascular disease, clinical data suggests that the determination of AtherOx, rather than oxLDL alone, is more predictive of the risk of progressive atherosclerotic cardiovascular disease. Four U.S. patents have been issued and several others are pending.
Products using the AtherOx(R) technology have not been cleared by the U.S. Food and Drug Administration for in vitro diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, products using this technology shall not be used for diagnostic use as the performance characteristics have not been established.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management's current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission, and in the Company's subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130910005383r1&sid=cmtx6&distro=nx
SOURCE: Corgenix Medical Corp.
Corgenix Medical Corp. Company Contact: William Critchfield, 303-453-8903 Senior VP and CFO WCritchfield@corgenix.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x 230 Vice President and Public Relations Supervisor dan@armadamedical.com
$CONX - Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
9:15 AM ET 9/10/13 | BusinessWire
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
The New Agreement grants a worldwide license to Corgenix, to utilize the AtherOx(R) technology to exclusively develop and manufacture, and co-exclusively sell diagnostic products during the term of the Agreement, which expires in 2022. In Japan, Corgenix will have the exclusive rights to utilize the AtherOx(R) technology to develop, manufacture and use, but not to sell the related AtherOx(R) products other than at the direction of Dr. Matsuura. Pursuant to the new Agreement, Corgenix will have to achieve certain specified milestones at each of the three anniversaries after the effective date (September 3, 2013).
Previous clinical data presented at several scientific and medical meetings demonstrated a significant correlation between serum levels of the patented AtherOx(R) bio-markers and cardiovascular disease. Luis Lopez, MD, Corgenix' Medical Director, said "Interestingly, data from the studies suggests that AtherOx alone or when combined with anti-phospholipid antibodies predict an increased risk for vascular complications in coronary artery disease patients. In addition, the findings indicate important relationships between AtherOx(R) and the severity of cardiovascular disease."
Commenting on today's announcement, Douglass Simpson, President and CEO of Corgenix, stated, "We are extremely excited to renew and expand our relationship with Dr. Matsuura and retain the rights to the AtherOx(R) technology. We believe this unique science targets a significant worldwide clinical need, and we look forward to seeing additional data over the next few years, leading to the opportunity to bring these products to the market. As new clinical findings continue to validate the utility of AtherOx(R), we anticipate that this technology has the potential to become an important addition to medical care worldwide."
About AtherOx(R)
Corgenix originally licensed the proprietary AtherOx(R) technology in 2002 from Dr. Matsuura. During the ensuing years, Corgenix has incorporated this technology into products, conducting multiple studies that further validate the impressive preclinical data generated by Professor Matsuura. The AtherOx(R) technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI (Ox LDL/B2GPI). Although oxLDL has been implicated in atherosclerotic cardiovascular disease, clinical data suggests that the determination of AtherOx, rather than oxLDL alone, is more predictive of the risk of progressive atherosclerotic cardiovascular disease. Four U.S. patents have been issued and several others are pending.
Products using the AtherOx(R) technology have not been cleared by the U.S. Food and Drug Administration for in vitro diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, products using this technology shall not be used for diagnostic use as the performance characteristics have not been established.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management's current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission, and in the Company's subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130910005383r1&sid=cmtx6&distro=nx
SOURCE: Corgenix Medical Corp.
Corgenix Medical Corp. Company Contact: William Critchfield, 303-453-8903 Senior VP and CFO WCritchfield@corgenix.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x 230 Vice President and Public Relations Supervisor dan@armadamedical.com
$CONX - Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
9:15 AM ET 9/10/13 | BusinessWire
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
The New Agreement grants a worldwide license to Corgenix, to utilize the AtherOx(R) technology to exclusively develop and manufacture, and co-exclusively sell diagnostic products during the term of the Agreement, which expires in 2022. In Japan, Corgenix will have the exclusive rights to utilize the AtherOx(R) technology to develop, manufacture and use, but not to sell the related AtherOx(R) products other than at the direction of Dr. Matsuura. Pursuant to the new Agreement, Corgenix will have to achieve certain specified milestones at each of the three anniversaries after the effective date (September 3, 2013).
Previous clinical data presented at several scientific and medical meetings demonstrated a significant correlation between serum levels of the patented AtherOx(R) bio-markers and cardiovascular disease. Luis Lopez, MD, Corgenix' Medical Director, said "Interestingly, data from the studies suggests that AtherOx alone or when combined with anti-phospholipid antibodies predict an increased risk for vascular complications in coronary artery disease patients. In addition, the findings indicate important relationships between AtherOx(R) and the severity of cardiovascular disease."
Commenting on today's announcement, Douglass Simpson, President and CEO of Corgenix, stated, "We are extremely excited to renew and expand our relationship with Dr. Matsuura and retain the rights to the AtherOx(R) technology. We believe this unique science targets a significant worldwide clinical need, and we look forward to seeing additional data over the next few years, leading to the opportunity to bring these products to the market. As new clinical findings continue to validate the utility of AtherOx(R), we anticipate that this technology has the potential to become an important addition to medical care worldwide."
About AtherOx(R)
Corgenix originally licensed the proprietary AtherOx(R) technology in 2002 from Dr. Matsuura. During the ensuing years, Corgenix has incorporated this technology into products, conducting multiple studies that further validate the impressive preclinical data generated by Professor Matsuura. The AtherOx(R) technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI (Ox LDL/B2GPI). Although oxLDL has been implicated in atherosclerotic cardiovascular disease, clinical data suggests that the determination of AtherOx, rather than oxLDL alone, is more predictive of the risk of progressive atherosclerotic cardiovascular disease. Four U.S. patents have been issued and several others are pending.
Products using the AtherOx(R) technology have not been cleared by the U.S. Food and Drug Administration for in vitro diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, products using this technology shall not be used for diagnostic use as the performance characteristics have not been established.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management's current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission, and in the Company's subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130910005383r1&sid=cmtx6&distro=nx
SOURCE: Corgenix Medical Corp.
Corgenix Medical Corp. Company Contact: William Critchfield, 303-453-8903 Senior VP and CFO WCritchfield@corgenix.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x 230 Vice President and Public Relations Supervisor dan@armadamedical.com
IMSC and ASEI - Two MA-based security equipment companies that have the eye of US Rep. John Tierney (D-MA):
Photo Release -- U.S. Representative John Tierney Visits AS&E
Massachusetts Congressman Discusses Border Security Technologies and Policies With AS&E Leadership
BILLERICA, Mass., Aug. 26, 2013 (GLOBE NEWSWIRE) -- U.S. Representative John F. Tierney (D-MA) today visited the offices of American Science and Engineering, Inc. ("AS&E") (ASEI), a leading worldwide supplier of innovative X-ray detection solutions. Rep. Tierney, the local member of Congress who has a key role in setting border security metrics, met with the Company's executive leadership to discuss developments in border security policies and viewed demonstrations of AS&E's advanced technologies that help secure borders and high profile locations around the world.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=20662
Rep. Tierney is the ranking Democrat on the House Oversight and Government Reform's Subcommittee on National Security, Homeland Defense and Foreign Operations. He also sits on the House Committee on Education and Workforce.
"The work that American Science and Engineering, Inc. does right here in Billerica is an excellent example of the cutting-edge research and development and state-of-the-art manufacturing flourishing in Massachusetts. I enjoyed meeting with leaders at AS&E to discuss border security technology and solutions," said Congressman John Tierney.
During the visit today, AS&E's President and CEO, Chuck Dougherty, emphasized the need for Congress to assure border entry points are fully secured to defeat illegal entry of persons as well as contraband that includes radiological materials and narcotics. Dougherty and Rep. Tierney also discussed the importance of the passage of comprehensive immigration reform legislation, and how it is critical to the nation's security and economic prosperity.
"It was a tremendous honor to host Congressman Tierney today," said Dougherty. "He provided us with valuable insight on the latest work on border security in Washington, and we in turn were able to demonstrate to him our products and solutions that are currently in-use at multiple border crossings for critical counter-drug and anti-terrorism missions. It was very helpful for both sides."
AS&E's systems are used to detect drugs, contraband, and illegal immigrants at border crossings around the world. Reported seizures as a result of the use of AS&E's detection solutions include 37,000 methamphetamine pills; $4 million of pirated and counterfeit goods; 8,400 lbs. of cocaine; 253 lbs. of marijuana; 9.45 lbs. of liquid methamphetamine; more than $800,000 of smuggled U.S. currency; 3,000 lbs. of drugs with a street value estimated at $31 million; 105,000 ecstasy tablets; and 1,000 gas bombs and 46 tasers.
About AS&E
American Science and Engineering, Inc. (AS&E) is the trusted global provider of threat and contraband detection solutions for ports, borders, military, critical infrastructure, law enforcement, and aviation. With over 50 years of experience, AS&E offers proven, advanced, X-ray inspection systems to combat terrorism, drug smuggling, illegal immigration and trade fraud. AS&E systems are designed in a variety of configurations for cargo and vehicle inspection, parcel inspection, and personnel screening. Using a combination of technologies, these systems provide superior detection capabilities, with high-energy, dual-energy, and Z Backscatter(TM) X-rays — pioneered by AS&E. Learn more about AS&E products and technologies at www.as-e.com.
It's all about industry-leading security technology yielding significant orders. No doubt this is what is currently fueling TASR to new-52 week highs:
TASER Announces Significant Smart Weapon Orders
SCOTTSDALE, AZ--(Marketwired - Aug 21, 2013) - TASER (NASDAQ: TASR) today announced multiple orders of its TASER® brand next generation Smart Weapons. These orders were received in the third quarter 2013 and are expected to ship in the third quarter.
Significant new TASER Smart Weapon deployments:
Fayetteville Police Department (NC): 200 TASER X2 Smart Weapons
Forsyth County Sheriff's Office (NC): 100 X2s with 100 TASER CAM HD recorders
Las Vegas Metro Police Department (NV): 174 TASER X26P Smart Weapons upgrade
Manatee County Sheriff's Office (FL): 100 X26Ps upgrade
Margate Police Department (FL): 103 X2s upgrade
Rhode Island State Police (RI): 170 X26Ps
USDA Forest Service: 200 X26Ps upgrade
Unnamed U.S. law enforcement agency: 237 X2s
Unnamed U.S. law enforcement agency: 600 X2s
Additional agencies ordering TASER Smart Weapons:
Alaska Department of Corrections (AK): X2s
Anne Arundel County Police Department (MD): X26Ps
Buncombe County Sheriff's Office (NC): X2s
City of Lakewood Police Department (CO): X26Ps
Clackamas County Jail (OR): X26Ps
Cumberland County Animal Services (NC): X26Ps upgrade
Davidson County Sheriff's Office (NC): X26Ps upgrade
Durham Police Department (NC): X2s
Eastern Shawnee Tribal Police (OK): X2s
Effingham Police Department (IL): X2s upgrade
Glen Ellyn Police Department (IL): X2s upgrade
Harris County Sheriff's Office (TX): X26Ps upgrade
Hazel Park Police Department (MI): X26Ps upgrade
Lake County Sheriff's Office (IN): X26Ps upgrade
Livingston Parish Sheriff's Office (LA): X26Ps
Madison Heights Police Department (MI): X2s and X26Ps upgrade
McKinney Police Department (TX): X2s
Naugatuck Police Department (CT): X2s
North Greenbush Police Department (NY): X26Ps
Pinecrest Police Department (FL): X26Ps
Portage County Sheriff's Office (OH): X26Ps
Rock Hill Police Department (SC): X2s upgrade
Sacramento County Sheriff's Department (CA): X26Ps upgrade
San Ramon Police Department (CA): X26Ps and TASER CAM HD recorders
Schaumburg Police Department (IL): X2s and TASER CAM HD recorders
Sedona Police Department (AZ): X26Ps upgrade
Southern Pines Police Department (NC): X26Ps and X2s
Texas Tech Police Department (TX): X26Ps
Trumbull County Family Court (OH): X26Ps
University of Texas at Brownsville (TX): X26Ps and TASER CAM HD recorders
University of Texas at Dallas Police Department (TX): X2s and TASER CAM HD recorders
Vacaville Police Department (CA): X2s and TASER CAM HD recorders upgrade
Venice Police Department (FL): X2s
Vienna Police Department (WV): X2s and TASER CAM HD recorders
Waco Police Department (TX): X2s upgrade
Watervliet Police Department (NY): X26Ps upgrade
Wichita Falls Police Department (TX): X26Ps
Wilmington Police Department (DE): X2s
Winnetka Police Department (IL): X2s
TASER Links
X2 Photos: http://www.taserbranding.com/law-enforcement-products/taser-cews/x2/press-images-2/
X26P Photos: http://www.taserbranding.com/law-enforcement-products/taser-cews/x26p/press-images/
International Websites:
Brazilian: http://br.taser.com/
French: http://fr.taser.com/
German: http://de.taser.com/
Spanish: http://es.taser.com/
United Kingdom: http://uk.taser.com/
TASER Social Media Links
Facebook: https://www.facebook.com/TASER.International
TASER Blog: http://blog.taser.com/
LinkedIn: http://www.linkedin.com/company/71228
YouTube: http://www.youtube.com/taserinternational1
Twitter: http://www.twitter.com/OfficialTASER
About TASER International, Inc.
TASER protects life: TASER Conducted Electrical Weapons (CEWs) have saved more than 110,000 lives from potential death or serious injury. TASER protects truth: We enable greater transparency with the industry-leading TASER CAM and AXON flex on-officer video systems. Together with our customers, we are defining the future of smart policing by connecting intelligent devices and sensors with the first secure cloud-based digital evidence management solution for law enforcement: EVIDENCE.com.
Since 1994, more than 260,000 private individuals have relied on TASER technology to protect themselves and their loved ones. Learn more about TASER and its solutions at www.TASER.com and www.EVIDENCE.com or by calling (800) 978-2737.
TASER® is a registered trademark of TASER International, Inc., registered in the U.S. All rights reserved. TASER logo, TASER X26P™, TASER X2™, TASER CAM™ HD, and AXON flex™ are trademarks of TASER International, Inc.
http://finance.yahoo.com/news/taser-announces-significant-smart-weapon-113000427.html
Breast implants suicide bomb threat: Heathrow on high alert over “credible” intelligence
UK Mirror - 16 Aug 2013
Security has been beefed up after intelligence al-Qaeda is plotting attacks on airlines flying out of London
Heathrow Airport is on high terror alert amid fears women suicide bombers are ready to strike with explosives concealed in breast implants.
Security checks have been beefed up after “credible” intelligence that al-Qaeda is plotting attacks on airlines flying out of London.
One staff member said: “There are genuine fears over this.
"We have been told to pay particular attention to females who may have concealed hidden explosives in their breasts.
“This is particularly difficult for us to pick up but we are on a very high state of alert.
“It’s led to long queues here at Heathrow – much longer than usual at this time of the year.
“But because it’s the summer holiday season, no one has complained.”
Al-Qaeda’s chief bomb-maker Ibrahim al-Asiri is understood to have developed the method of foiling airport scanners by concealing explosives in an implant or bodily cavity.
It is also feared there is no shortage of volunteers willing to take part in an atrocity after hundreds of extremists recently escaped from prison in Pakistan.
Explosives expert Andy Oppenheimer said: “There is a great fear that al-Qaeda are planning on using internal devices to try and get through airport scanners.
"These explosives could be in breast implants.”
Another specialist, who asked not to be named, said breast implant bombs could be set off by injecting another liquid.
The expert added: “Both are very difficult to pick up with current technology and they are petrified al-Qaeda are a step ahead here.
“It’s pretty top secret and potentially very grisly and ghastly.”
Independent security analyst Paul Beaver said: “There are currently deeply serious concerns over body cavities and implants of all kinds – including breast implants – being used to hide explosives.
"It is taking longer to get through Heathrow and other airports in Europe and North America because of these fears.
“They are taking longer to screen people and there is definitely some sort of profiling going on.
“The general alert state remains the same in the UK but overseas, the recent Pakistan prison breakouts and foiled attacks in Yemen are raising fears of a new jihadist wave of violence.”
Terrorists are believed to be plotting attacks with the explosive pentaerythritol tetranitrate, or PETN.
It is also feared they may have developed an undetectable liquid explosive that could be soaked into clothing.
For a suicide bomber sat in a window seat it would take only a relatively small blast to blow a lethal hole in a plane’s fuselage.
Mr Beaver added: “The terrorist is getting clever, but so are detection methods.
“The fact we know about the new methods suggests there are detection and counter-measure options.
“Implant bombs are a one-way ticket anyway so the suicide bomber won’t care what the trigger might be.
"It would have to be simple and straightforward – perhaps electrical.”
A Heathrow Airport spokesman said: “We don’t comment on specific security measures.”
Scans won't detect them: Expert view by Philip Baum, Editor of Security International
The possibility of medically implanted explosives is a concern to the industry.
There are two main ways of initiating a detonation – by chemical reaction or radio controlled detonators.
The problem is another reason why we should be using behavioural analysis as the primary detection method to screen people at airports.
Body scanners are good at identifying things outside the body but not inside.
Whether or not implants would make effective explosive devices in passenger planes is also questionable.
The examples we have seen haven’t quite had the impact those behind them might have hoped for.
http://www.mirror.co.uk/news/uk-news/breast-implants-suicide-bomb-threat-2172911#ixzz2c8lcoFEL
UK to boost JNIA security
By Gerald Kitabu
16th August 2013
The British High Commissioner, Dianna Melrose is today expected to handover two explosive trace detection machines, consumables and other aviation security equipment to the government of Tanzania.
The machines and equipment will assist in broadening aviation security, specifically detection capability at Tanzanian airports.
According to a press release unveiled to the media yesterday, the British envoy will also present certificates to the Tanzanian Airports Authority (TAA) staff who have successfully participated in the UK sponsored explosive trace detection training courses at the Julius Nyerere International Airport in Dar es Salaam.
She said terrorism is a global issue and the British government is keen to maintain its close working relationship with Tanzania in order to strengthen the existing aviation security regime and work together to tackle terrorist threats.
The UK Department for Transport (DfT) has regional staff based in East Africa who will be working to maintain the close and productive working relationship with the TAA and the Tanzanian Civil Aviation Authority.
SOURCE: THE GUARDIAN